Alpelisib + Tamoxifen + Zotatifin + Fulvestrant
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer
Trial Timeline
Mar 20, 2023 → Jun 3, 2024
NCT ID
NCT05101564About Alpelisib + Tamoxifen + Zotatifin + Fulvestrant
Alpelisib + Tamoxifen + Zotatifin + Fulvestrant is a phase 2 stage product being developed by eFFECTOR Therapeutics for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05101564. Target conditions include Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05101564 | Phase 2 | Completed |
Competing Products
20 competing products in Breast Cancer